Celgene Corporation (CELG): Today's Featured Drugs Winner

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

Celgene Corporation ( CELG) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day up 0.5%. By the end of trading, Celgene Corporation rose $2.38 (2.0%) to $121.64 on average volume. Throughout the day, 2,854,096 shares of Celgene Corporation exchanged hands as compared to its average daily volume of 3,217,100 shares. The stock ranged in a price between $119.81-$121.90 after having opened the day at $120.22 as compared to the previous trading day's close of $119.26. Other companies within the Drugs industry that increased today were: China Pharma ( CPHI), up 9.3%, Neptune Technologies & Bioressources ( NEPT), up 9.3%, TrovaGene ( TROV), up 8.0% and pSivida ( PSDV), up 7.8%.
  • EXCLUSIVE OFFER: Jim Cramer's Protege, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Celgene Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of various therapies to treat cancer and immune-inflammatory related diseases in the United States, Europe, and other countries. Celgene Corporation has a market cap of $48.7 billion and is part of the health care sector. The company has a P/E ratio of 35.5, above the S&P 500 P/E ratio of 17.7. Shares are up 48.7% year to date as of the close of trading on Thursday. Currently there are 23 analysts that rate Celgene Corporation a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates Celgene Corporation as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, solid stock price performance and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income.

On the negative front, Delcath Systems ( DCTH), down 42.0%, Aoxing Pharmaceutical Company ( AXN), down 16.0%, Sangamo BioSciences ( SGMO), down 10.3% and Arena Pharmaceuticals ( ARNA), down 9.2% , were all laggards within the drugs industry with Vertex Pharmaceuticals ( VRTX) being today's drugs industry laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.